Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1273.211
- Development stage
- Phase 3
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1273.211 is a bivalent, investigational COVID-19 vaccine booster developed by Moderna. It utilizes messenger RNA (mRNA) technology to encode the spike glycoproteins of both the original Wuhan-Hu-1 strain and the Beta (B.1.351) variant of SARS-CoV-2, delivered via lipid nanoparticles[2][4]. The vaccine is designed to broaden immune protection against multiple variants of concern, including Beta, Delta, and Omicron[1][4][6]. In clinical studies, a 50 µg booster dose demonstrated superior neutralizing antibody responses compared to Moderna's first-generation mRNA-1273 booster against these variants at one month post-vaccination; this superiority persisted for Beta and Omicron at six months[1][5][8]. The safety profile was similar to that of the authorized mRNA-1273 booster at equivalent doses[2][5].
- Other names
- mRNA-1273.211mRNA1273.211mRNA 1273.211multivalent mRNA-1273 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on mRNA-1273.211.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1273.211.